Literature DB >> 19168733

Intralesional regulatory T-cell suppressive function during human acute and chronic cutaneous leishmaniasis due to Leishmania guyanensis.

E Bourreau1, C Ronet, E Darcissac, M C Lise, D Sainte Marie, E Clity, F Tacchini-Cottier, P Couppie, P Launois.   

Abstract

The levels of regulatory T cells (Treg cells), analyzed by Foxp3 mRNA expression, were determined in lesions from patients with acute cutaneous leishmaniasis (ACL) and chronic cutaneous leishmaniasis (CCL). We demonstrated that Treg cells preferentially accumulate in lesions from ACL patients during the early phase of infection (lesion duration of less than 1 month). In addition, levels of Foxp3 mRNA transcripts were significantly higher in specimens from patients with CCL than in those from patients with ACL, suggesting a critical role of intralesional Treg cells in CCL. Intralesional Treg cells from both ACL and CCL patients were shown to have suppressive functions in vitro, since they inhibited the gamma interferon (IFN-gamma) produced by CD4(+) CD25(-) T cells purified from peripheral blood mononuclear cells from the same patient in response to Leishmania guyanensis stimulation. Intralesional 2,3-indoleamine dioxygenase (IDO) mRNA expression was associated with that of Foxp3, suggesting a role for IDO in the suppressive activity of intralesional Treg cells. In addition, a role, albeit minor, of interleukin-10 (IL-10) was also demonstrated, since neutralization of IL-10 produced by intralesional T cells increased IFN-gamma production by effector cells in an in vitro suppressive assay. These results confirm the role of intralesional Treg cells in the immunopathogenesis of human Leishmania infection, particularly in CCL patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168733      PMCID: PMC2663152          DOI: 10.1128/IAI.01398-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.

Authors:  G A Romero; M V Guerra; M G Paes; V O Macêdo
Journal:  Am J Trop Med Hyg       Date:  2001-11       Impact factor: 2.345

2.  CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity.

Authors:  Yasmine Belkaid; Ciriaco A Piccirillo; Susana Mendez; Ethan M Shevach; David L Sacks
Journal:  Nature       Date:  2002-12-05       Impact factor: 49.962

3.  T cell apoptosis by tryptophan catabolism.

Authors:  F Fallarino; U Grohmann; C Vacca; R Bianchi; C Orabona; A Spreca; M C Fioretti; P Puccetti
Journal:  Cell Death Differ       Date:  2002-10       Impact factor: 15.828

4.  Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Jeffrey R Lee; Kanchan G Jhaver; Theodore S Johnson; Derin B Keskin; Brendan Marshall; Phillip Chandler; Scott J Antonia; Russell Burgess; Craig L Slingluff; Andrew L Mellor
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

5.  CTLA-4-Ig regulates tryptophan catabolism in vivo.

Authors:  Ursula Grohmann; Ciriana Orabona; Francesca Fallarino; Carmine Vacca; Filippo Calcinaro; Alberto Falorni; Paola Candeloro; Maria L Belladonna; Roberta Bianchi; Maria C Fioretti; Paolo Puccetti
Journal:  Nat Immunol       Date:  2002-09-30       Impact factor: 25.606

6.  The early IL-4 response to Leishmania major and the resulting Th2 cell maturation steering progressive disease in BALB/c mice are subject to the control of regulatory CD4+CD25+ T cells.

Authors:  Abraham Aseffa; Alain Gumy; Pascal Launois; H Robson MacDonald; Jacques A Louis; Fabienne Tacchini-Cottier
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

7.  Th2 responses predominate during the early phases of infection in patients with localized cutaneous leishmaniasis and precede the development of Th1 responses.

Authors:  Eliane Bourreau; Jacques Gardon; Roger Pradinaud; Hervé Pascalis; Ghislaine Prévot-Linguet; Amina Kariminia; Launois Pascal
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

8.  Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.

Authors:  S Read; V Malmström; F Powrie
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

9.  Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites.

Authors:  Peter Terness; Thomas M Bauer; Lars Röse; Christoph Dufter; Andrea Watzlik; Helmut Simon; Gerhard Opelz
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

10.  Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase.

Authors:  Guido Frumento; Rita Rotondo; Michela Tonetti; Gianluca Damonte; Umberto Benatti; Giovanni Battista Ferrara
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

View more
  38 in total

1.  Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression.

Authors:  Levi H C Makala; Babak Baban; Henrique Lemos; Ahmed R El-Awady; Phillip R Chandler; De-Yan Hou; David H Munn; Andrew L Mellor
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

Review 2.  Inflammation and adaptive immunity in Parkinson's disease.

Authors:  R Lee Mosley; Jessica A Hutter-Saunders; David K Stone; Howard E Gendelman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

3.  Regulatory T-Cell Dynamics in Cutaneous and Mucocutaneous Leishmaniasis due to Leishmania braziliensis.

Authors:  Nicolas Barros; Nestor Vasquez; Fernando Woll; Cesar Sanchez; Braulio Valencia; Alejandro Llanos-Cuentas; A Clinton White; Martin Montes
Journal:  Am J Trop Med Hyg       Date:  2018-02-01       Impact factor: 2.345

4.  Effector memory CD4(+) T cells differentially express activation associated molecules depending on the duration of American cutaneous leishmaniasis lesions.

Authors:  C de Oliveira Mendes-Aguiar; R Vieira-Gonçalves; L H Guimarães; M P de Oliveira-Neto; E M Carvalho; A M Da-Cruz
Journal:  Clin Exp Immunol       Date:  2016-06-06       Impact factor: 4.330

Review 5.  The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis.

Authors:  Mary-Anne Hartley; Stefan Drexler; Catherine Ronet; Stephen M Beverley; Nicolas Fasel
Journal:  Trends Parasitol       Date:  2014-06-20

Review 6.  Interleukin-10 and immunity against prokaryotic and eukaryotic intracellular pathogens.

Authors:  Joshua C Cyktor; Joanne Turner
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

7.  Interleukin 10 and dendritic cells are the main suppression mediators of regulatory T cells in human neurocysticercosis.

Authors:  A Arce-Sillas; D D Álvarez-Luquín; G Cárdenas; D Casanova-Hernández; G Fragoso; M Hernández; J V Proaño Narváez; F García-Vázquez; A Fleury; E Sciutto; L Adalid-Peralta
Journal:  Clin Exp Immunol       Date:  2015-11-11       Impact factor: 4.330

8.  The immunotherapeutic role of regulatory T cells in Leishmania (Viannia) panamensis infection.

Authors:  Allison Ehrlich; Tiago Moreno Castilho; Karen Goldsmith-Pestana; Wook-Jin Chae; Alfred L M Bothwell; Tim Sparwasser; Diane McMahon-Pratt
Journal:  J Immunol       Date:  2014-08-06       Impact factor: 5.422

9.  Immunological perspectives of leishmaniasis.

Authors:  Susanne Nylén; Shalini Gautam
Journal:  J Glob Infect Dis       Date:  2010-05

10.  Plasmodium vivax: induction of CD4+CD25+FoxP3+ regulatory T cells during infection are directly associated with level of circulating parasites.

Authors:  Lilian Lacerda Bueno; Cristiane Guimarães Morais; Fernanda Fortes Araújo; Juliana Assis Silva Gomes; Rodrigo Corrêa-Oliveira; Irene Silva Soares; Marcus Vinícius Lacerda; Ricardo Toshio Fujiwara; Erika Martins Braga
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.